Ironwood Pharmaceuticals (NASDAQ: IRWD) reported disappointing third-quarter earnings results on Tuesday, sending its shares sharply lower in pre-market trading. The biopharmaceutical company's adjusted earnings per share missed Wall Street's expectations by a wide margin, overshadowing a slight revenue beat.
For the quarter ended September 30, 2024, Ironwood posted adjusted earnings of $0.02 per share, falling significantly short of the consensus estimate of $0.08 per share. This represented an 83.3% decline compared to the prior-year quarter.
Revenue for the quarter came in at $91.6 million, narrowly surpassing analysts' projections of $91.2 million but marking a 19.5% decrease from the same period last year. The decline was primarily driven by lower sales of Ironwood's flagship drug LINZESS due to pricing pressures in the U.S. market.
Despite the disappointing quarterly performance, Ironwood maintained its full-year 2024 financial guidance, projecting total revenue in the range of $350 million to $375 million and adjusted EBITDA above $75 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。